22 June 2020
*A corporate client of Hybridan LLP
Dish of the day
No Joiners Today
Off the menu
No Leavers Today
What’s cooking in the IPO kitchen?
The pantry is bare!
Banquet Buffet
Physiomics* 6.6p £6.3m (LON:PYC)
The provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is participating in the American Academy of Cancer Research (AACR) Annual Meeting 2020, being held as a virtual event.
The Company will be presenting on a new version of its Virtual Tumour™ model, which is able to simulate the efficacy of dual immuno-therapy regimens. The model was originally developed as part of a client project.
The Company will be presenting an original poster in the session "LBPO.IM02 - Late-Breaking Research: Immunology 2", scheduled for 22 June 2020 at 9.00 a.m. - 6.00 p.m. EDT (Eastern Daylight Time). The poster is titled "Optimising dual immuno-oncology combinations with Virtual Tumour" (Abstract # LB-392). The session will include live interactions and the poster will remain available for viewing by registered attendees for at least three months after the virtual meeting.
Vast Resources 0.1975p £22.3m (LON:VAST)
Vast has raised £1.5m at 0.18m. The cash raised from the Placing together with further subscription proceeds as referred to above will provide funds to cash settle the liability to Atlas Capital Markets at the end of July or during August 2020, should Atlas decide to exercise its conversion rights prior to the Company finalising the refinancing announced on 15 May 2020. At current share prices, the necessary sum to achieve this is estimated by the Directors to be of the order of US$780,000 As announced on 24 October 2019 under the Atlas Bond Issue Deed there is a six months non-conversion period from the drawdown date (30 January 2020) after which Atlas may convert up to 10% of the par value of the Bond each month.
In addition, the funds being raised will provide the Company with funding for the first month’s production at the Baita Plai Polymetallic Mine until the first sale of concentrate expected in late August, together with some further general working capital.
FastForward Innovations 6.25p £10.1m (LON:FFWD)
The company focusing on making investments in fast growing and industry leading businesses, is pleased to note the update from 888Sport relating to its partnership with Leap Gaming, in which FastForward has a 43.4% interest in through its investee company, Fralis LLC. Leap Gaming's partnership with 888 will see a variety of Leap Gaming titles become available through 888casino . The partnership will see 888sport host a selection of popular, ultra-realistic 3D virtual sports games from Leap Gaming.
SolGold 21.125p £438m (LON:SOLG)
Update on the Company's regional exploration programme throughout Ecuador. Following the hiatus of all activities due to the COVID-19 pandemic and government restrictions, SolGold has resumed exploration activities on a number of concessions with strict COVID-19 protocols in place.
Highlights
Ø All regulatory approvals received for scout drilling at Porvenir, La Hueca and Blanca projects Ø Drilling equipment mobilised to Porvenir, with logistics and camp construction nearing completion Ø A drill rig is preparing to move to the La Hueca Project Ø Regional exploration programme fully funded alongside the Company's pre-feasibility study at Alpala, following recent successful capital raising
Ø Ecuadorean government publicly recognised the critical role mineral mining and exploration industry will play in rebuilding national and local economies post COVID-19 Ø National authorities encouraging return to productive activities Ø Field activities resumed at other priority regional projects including Rio Amarillo, Chical, Cisne-Loja, Sharug and Timbara Ø SolGold working closely with all levels of government, particularly local COVID-19 Emergency Committees to ensure certain protocols are met to safely restart activities
Directa Plus 75p £45.75m (LON:DCTA)
The producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company has been granted its sixth Chinese patent. The grant by the Chinese Patent Office covers the use of the Company's G+® graphene technology for bicycle, motorcycle and passenger car tyres as well as truck and bus radial tyres.
Specifically, the patent covers the formula which unlocks the potential of G+® technology for the tread component and enables manufacturers to balance the conflicting properties of rolling resistance and grip while enhancing both.
China is one of the main manufacturers of elastomeric compounds for the global tyre industry. The country's own tyre market was estimated to be worth some US$28 billion in 2018 by TechSci Research which forecast the market to grow at a compound annual rate of over ten per cent to reach US$52 billion by 2023.
Blackbird 15.75p £52.9m (LON:BIRD)
The developer and seller of the market-leading Blackbird cloud video editing platform, announced today that esports trailblazers, VENN, have selected Blackbird for ultra-fast and efficient remote video production. The deal is for 3 years and was brokered by Blackbird's new US systems integrator partner, ASG.
VENN is a new kind of TV network for the streaming generation, aimed at gaming, pop culture and esports audiences. Founded by gaming visionaries Ariel Horn and Ben Kusin, VENN broadcasts live from studios in New York and Los Angeles with content distributed across a broad range of media platforms.
Brave Bison 1.375p £8.4m (LON:BBSN)
Social video company Brave Bison recently teamed up with the Internet Watch Foundation (IWF) and the Marie Collins Foundation (MCF) to raise awareness of their child sexual abuse education campaign, "Something's Not Right". Comedian Arron Crascall and football YouTuber EmanSV2 were enlisted to participate in the campaign, which focused on encouraging and empowering young men to report sexual images of children online. Manning Gottlieb OMD brokered the appointment and Brave Bison was selected based on the team's expertise and proven success in influencer marketing.
The talent-led campaign was hugely successful with Arron Crascall and EmanSV2 driving over 8.5 million user impressions and more than 5.4 million views on Instagram, meaning that Brave Bison delivered 23x higher engagement, 15x more impressions and 37x more views than expected. Further, compared to the average non-profit industry Instagram engagement rate of 1.75% and the average influencer industry Instagram engagement rate of 1.67%, the campaign's average engagement rate was 6.9% - nearly 4x higher than the industry average.
Active Energy 0.9p £11.5m (LON:AEG)
The international biomass based renewable energy business, is pleased to announce that it has completed a fundraise of £800,000 (before expenses) through the subscription of convertible loan notes by new US and existing European investors. The CLNs are being issued as part of the Company's existing Series B CLN Instrument.
Highlights:
· £800,000 raised through the issuance of CLNs with the proceeds immediately deployed to accelerate the development of and increase production volumes at AEG's Lumberton facility ("Lumberton")
· Existing sawmill's 2nd production shift to start mid-July
· Additional saw-log export contract signed with a new South East Asian customer
· New sales & commercial opportunities being presented to the Company at Lumberton
MYCELX 46.5p £9m (LON:MYX)
The clean water technology company providing patented solutions for the Oil and Gas market and commercial industrial markets worldwide, announced the extension of a purchase order from SABIC (Saudi Basic Industries Corporation).
The contract extension with SABIC is for a leased water treatment system in the Middle East. The value of the contract extension is $1.8m. The Company continues to pursue advanced opportunities in the Middle East and to that end has agreed to run a trial at another SABIC affiliate which, if successful, has the potential to generate further incremental revenues for the Company this year.
Angle 62.5p £108m (LON:AGL)
The liquid biopsy company, is announced that blood donations have recommenced in support of ANGLE's FDA analytical studies and for patient enrolment in its pivotal ovarian cancer study.
As announced on 31 March 2020, completion of ANGLE's remaining analytical studies in support of its US Food and Drug Administration (FDA) submission for Parsortix® had to be ceased as a result of UK Government COVID-19 lock down measures preventing blood donations from healthy volunteers. Similar restrictions in the United States impacted patient enrolment at University of Rochester Medical Centre, New York for the ovarian cancer study there.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
Head Chef
Derren Nathan
0203 764 2344
derren.nathan@hybridan.com